Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1α stability.

Triple-negative breast cancers (TNBCs) are characterized by high rates of recurrence and poor clinical outcomes. Deregulated E3 ligases are involved in breast cancer pathogenesis and progression, but the underlying mechanisms are unclear. Here, we find that F-box and leucine-rich repeat protein 16 (FBXL16) acts as a tumor suppressor in TNBCs. FBXL16 directly binds to HIF1α and induces its ubiquitination and degradation, regardless of the tumor microenvironment, resulting in blockade of the HIF1α-mediated epithelial-mesenchymal transition (EMT) and angiogenesis features of breast cancer. In TNBCs, FBXL16 expression is downregulated by the p38/miR-135b-3p axis, and loss of FBXL16 expression restores HIF1α-mediated metastatic features of breast cancer. Low expression of FBXL16 is associated with high-grade and lymph node-positive tumors and poor overall survival of breast cancer. Taken together, these findings demonstrate that modulation of FBXL16 expression may offer a favorable strategy for treatment of patients with metastatic breast cancer, including TNBCs.

[1]  Zhuo-wei Hu,et al.  Resistomycin attenuates triple-negative breast cancer progression by inhibiting E3 ligase Pellino-1 and inducing SNAIL/SLUG degradation , 2020, Signal Transduction and Targeted Therapy.

[2]  Weiwen Long,et al.  The F-box protein FBXL16 up-regulates the stability of C-MYC oncoprotein by antagonizing the activity of the F-box protein FBW7 , 2020, The Journal of Biological Chemistry.

[3]  S. Tam,et al.  Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond , 2020, Frontiers in Oncology.

[4]  I. Hwang,et al.  Molecular and Cellular Response of Co-cultured Cells toward Cobalt Chloride (CoCl2)-Induced Hypoxia , 2019, ACS omega.

[5]  A. Ooshima,et al.  RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers , 2019, Nature Communications.

[6]  N. Alitheen,et al.  The Regulatory Role of MicroRNAs in Breast Cancer , 2019, International journal of molecular sciences.

[7]  M. Iorio,et al.  Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer , 2018, Scientific Reports.

[8]  C. Denkert,et al.  Molecular alterations in triple-negative breast cancer—the road to new treatment strategies , 2017, The Lancet.

[9]  Jingyuan Fang,et al.  LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation , 2016, Journal of Experimental & Clinical Cancer Research.

[10]  L. Pfeffer,et al.  MicroRNA regulation of F-box proteins and its role in cancer. , 2016, Seminars in cancer biology.

[11]  H. Laman,et al.  F-box protein interactions with the hallmark pathways in cancer. , 2016, Seminars in cancer biology.

[12]  Leng Han,et al.  The LINK-A lncRNA Activates Normoxic HIF1α Signaling in Triple-negative Breast Cancer , 2016, Nature Cell Biology.

[13]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[14]  Rodney J. Scott,et al.  Novel genes associated with lymph node metastasis in triple negative breast cancer , 2015, Scientific Reports.

[15]  G. Semenza,et al.  Hypoxia-inducible factor 1 and breast cancer metastasis , 2015, Journal of Zhejiang University-SCIENCE B.

[16]  J. Wiest,et al.  Endothelial cell tube formation assay for the in vitro study of angiogenesis. , 2014, Journal of visualized experiments : JoVE.

[17]  Peter T. Simpson,et al.  Molecular classification of breast cancer , 2014, Virchows Archiv.

[18]  Denis Wirtz,et al.  Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.

[19]  Zhiwei Wang,et al.  Roles of F-box proteins in cancer , 2014, Nature Reviews Cancer.

[20]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[21]  Michael J. Sweredoski,et al.  F-box Protein FBXL16 Binds PP2A-B55α and Regulates Differentiation of Embryonic Stem Cells along the FLK1+ Lineage* , 2014, Molecular & Cellular Proteomics.

[22]  G. Mills,et al.  Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors , 2013, Oncogene.

[23]  L. O’Driscoll,et al.  Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. , 2013, Carcinogenesis.

[24]  J. Foekens,et al.  miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs , 2013, Breast Cancer Research.

[25]  Kou-Juey Wu,et al.  Hypoxia-regulated target genes implicated in tumor metastasis , 2012, Journal of Biomedical Science.

[26]  G. Semenza.  Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. , 2012, Trends in molecular medicine.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[28]  S. Bicciato,et al.  SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors , 2012, Nature.

[29]  A. Howe,et al.  Negative regulation of HIF‐1α by an FBW7‐mediated degradation pathway during hypoxia , 2011, Journal of cellular biochemistry.

[30]  Daniel Birnbaum,et al.  A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.

[31]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[32]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Xavier Estivill,et al.  Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness , 2010, Cancer.

[34]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[35]  Kenichi Yoshida,et al.  FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells. , 2009, International journal of oncology.

[36]  E. Lewis,et al.  Aortic Ring Assay , 2009, Journal of visualized experiments : JoVE.

[37]  Zhongmei Zhou,et al.  KLF5 Promotes Breast Cell Survival Partially through Fibroblast Growth Factor-binding Protein 1-pERK-mediated Dual Specificity MKP-1 Protein Phosphorylation and Stabilization* , 2009, The Journal of Biological Chemistry.

[38]  Xiao-Jun Ma,et al.  Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.

[39]  Yili Yang,et al.  Targeting the ubiquitin‐proteasome system for cancer therapy , 2009, Cancer science.

[40]  K. Takeda,et al.  Role and regulation of prolyl hydroxylase domain proteins , 2008, Cell Death and Differentiation.

[41]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[42]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[43]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[44]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[46]  Christopher J. Schofield,et al.  Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.

[47]  P. Ratcliffe,et al.  Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.

[48]  P. Polakis.  More Than One Way to Skin a Catenin , 2001, Cell.

[49]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[50]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Stephen J. Elledge,et al.  SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.